Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR0534 in Chinese Type 2 Diabetic Patients
NCT03006159Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of SHR0534 in type 2 diabetes mellitus (T2DM) (3 cohorts), sponsored by Hengrui. Primary endpoints: Number of treatment emergent adverse events at Day 38, Area under the plasma concentration curve at 192 hours and 3 more. Started Mar 2015; status: completed.
02
Drugs
SHR0534
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03006159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006159.